Graphene Investments SAS Has $3.47 Million Holdings in Pfizer Inc. $PFE

Graphene Investments SAS boosted its stake in Pfizer Inc. (NYSE:PFE) by 24.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,200 shares of the biopharmaceutical company’s stock after acquiring an additional 27,700 shares during the period. Pfizer accounts for 2.3% of Graphene Investments SAS’s investment portfolio, making the stock its 7th largest holding. Graphene Investments SAS’s holdings in Pfizer were worth $3,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter worth $27,000. Curio Wealth LLC grew its holdings in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Stock Performance

Shares of PFE stock opened at $24.64 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $24.74 and a two-hundred day simple moving average of $24.33. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.99. The firm has a market capitalization of $140.09 billion, a PE ratio of 13.11, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.